Literature DB >> 21802427

Structural basis of binding by cyclic nonphosphorylated peptide antagonists of Grb7 implicated in breast cancer progression.

Nigus D Ambaye1, Stephanie C Pero, Menachem J Gunzburg, MinYin Yap, Daniel J Clayton, Mark P Del Borgo, Patrick Perlmutter, Marie-Isabel Aguilar, Girja S Shukla, Elena Peletskaya, Michelle M Cookson, David N Krag, Matthew C J Wilce, Jacqueline A Wilce.   

Abstract

Growth-receptor-bound protein (Grb)7 is an adapter protein aberrantly overexpressed, along with the erbB-2 receptor in breast cancer and in other cancers. Normally recruited to focal adhesions with a role in cell migration, it is associated with erbB-2 in cancer cells and is found to exacerbate cancer progression via stimulation of cell migration and proliferation. The G7-18NATE peptide (sequence: WFEGYDNTFPC cyclized via a thioether bond) is a nonphosphorylated peptide that was developed for the specific inhibition of Grb7 by blocking its SH2 domain. Cell-permeable versions of G7-18NATE are effective in the reduction of migration and proliferation in Grb7-overexpressing cells. It thus represents a promising starting point for the development of a therapeutic against Grb7. Here, we report the crystal structure of the G7-18NATE peptide in complex with the Grb7-SH2 domain, revealing the structural basis for its interaction. We also report further rounds of phage display that have identified G7-18NATE analogues with micromolar affinity for Grb7-SH2. These peptides retained amino acids F2, G4, and F9, as well as the YDN motif that the structural biology study showed to be the main residues in contact with the Grb7-SH2 domain. Isothermal titration calorimetry measurements reveal similar and better binding affinity of these peptides compared with G7-18NATE. Together, this study facilitates the optimization of second-generation inhibitors of Grb7.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21802427     DOI: 10.1016/j.jmb.2011.07.030

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  12 in total

1.  Preparation of crystals for characterizing the Grb7 SH2 domain before and after complex formation with a bicyclic peptide antagonist.

Authors:  Nigus D Ambaye; Menachem J Gunzburg; Daouda A K Traore; Mark P Del Borgo; Patrick Perlmutter; Matthew C J Wilce; Jacqueline A Wilce
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-01-21       Impact factor: 1.056

2.  Water-refined solution structure of the human Grb7-SH2 domain in complex with the erbB2 receptor peptide pY1139.

Authors:  Sally C Pias; Dennis L Johnson; David E Smith; Barbara A Lyons
Journal:  Protein Pept Lett       Date:  2012-08       Impact factor: 1.890

Review 3.  Targeting SH2 domains in breast cancer.

Authors:  Pietro Morlacchi; Fredika M Robertson; Jim Klostergaard; John S McMurray
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

4.  Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.

Authors:  Manman Zeng; Zhu Yang; Xiaoyu Hu; Yi Liu; Xiaotao Yang; Hailong Ran; Yanan Li; Xu Li; Qiubo Yu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

5.  An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma.

Authors:  Genta Sawada; Atsushi Niida; Hidenari Hirata; Hisateru Komatsu; Ryutaro Uchi; Teppei Shimamura; Yusuke Takahashi; Junji Kurashige; Tae Matsumura; Hiroki Ueo; Yuki Takano; Masami Ueda; Shotaro Sakimura; Yoshiaki Shinden; Hidetoshi Eguchi; Tomoya Sudo; Keishi Sugimachi; Makoto Yamasaki; Fumiaki Tanaka; Yuji Tachimori; Yoshiaki Kajiyama; Shoji Natsugoe; Hiromasa Fujita; Yoichi Tanaka; George Calin; Satoru Miyano; Yuichiro Doki; Masaki Mori; Koshi Mimori
Journal:  PLoS One       Date:  2015-10-14       Impact factor: 3.240

6.  Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways.

Authors:  Kangmei Chen; Michelle Xin Liu; Celia Sze-Ling Mak; Mingo Ming-Ho Yung; Thomas Ho-Yin Leung; Dakang Xu; Siew-Fei Ngu; Karen Kar-Loen Chan; Huijuan Yang; Hextan Yuen-Sheung Ngan; David Wai Chan
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556

7.  Grb7-derived calmodulin-binding peptides inhibit proliferation, migration and invasiveness of tumor cells while they enhance attachment to the substrate.

Authors:  Juan Alcalde; María González-Muñoz; Antonio Villalobo
Journal:  Heliyon       Date:  2020-05-07

8.  Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.

Authors:  David W Chan; Winnie W Y Hui; Patty C H Cai; Michelle X Liu; Mingo M H Yung; Celia S L Mak; Thomas H Y Leung; Karen K L Chan; Hextan Y S Ngan
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

9.  Unexpected involvement of staple leads to redesign of selective bicyclic peptide inhibitor of Grb7.

Authors:  Menachem J Gunzburg; Ketav Kulkarni; Gabrielle M Watson; Nigus D Ambaye; Mark P Del Borgo; Rebecca Brandt; Stephanie C Pero; Patrick Perlmutter; Matthew C J Wilce; Jacqueline A Wilce
Journal:  Sci Rep       Date:  2016-06-03       Impact factor: 4.379

10.  Insight into the Selectivity of the G7-18NATE Inhibitor Peptide for the Grb7-SH2 Domain Target.

Authors:  Gabrielle M Watson; William A H Lucas; Menachem J Gunzburg; Jacqueline A Wilce
Journal:  Front Mol Biosci       Date:  2017-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.